reason report
hurt regeneron short-term top long-term
bottom line outbreak continu escal
us eu found caus extens disrupt
healthcar system particularli provis in-offic medic
eylea experi materi signific revenu eros
mid-march least end multipl sourc
medacorp kol call secondari databas suggest sharp
declin in-person offic visit mid-march addit emerg
product dupix higher proport revenu new
patient expect neg impact well howev
believ impact like temporari eylea
dupix eylea dupix long-term growth
beyond remain larg intact
delay antibodi collabor restructur guidanc
announc clinic program remain track base
current situat repurpos kevzara program
expect delay regeneron antibodi collabor amend
sanofi mp origin schedul close end also
expect compani announc guidanc later date
accordingli clinic side expect compani report
libtayo basal cell carcinoma pivot data mid year non-smal
cell lung cancer os interim data second half trial
near fulli enrol base recent call manag
team regeneron suggest suffici inventori
commerci product avoid suppli disrupt
reduc svbl revenu forecast account
weaker eylea demand due relat offic shut down
elderli observ social distanc expect materi treatment
delay cancel eylea late base
estim us eylea march inject
expect reschedul inject go
delay similarli assum signific treatment delays/
cancel eylea ou busi us eylea forecast
decreas remain rel
unchang ou eylea forecast bayer collabor
also went slightli increas
besid eylea also expect moder impact
dupix new patient start new indic like slower
although exist patient continu receiv drug
mail fulfil global dupix forecast declin
compani inform svb leerink llc research
revenu mm dilut ep non-gaap
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
combin total revenu forecast decreas
remain unchang
updat revenu forecast consensu
remain higher rel consist
expens estim non-gaap ep estim come
materi non-gaap ep
estim latest consensu remain higher
despit lower revenu ep forecast
long-term view regeneron stock remain unchang adjust
valuat metric price target remain unchang
reiter outperform rate regeneron stock
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani grow strongli base success
first truli novel medicin dupix allerg diseas first product eylea continu
surpris investor taken grown market intraocular vegf vascular
endotheli growth factor antibodi treatment eylea contribut global sale
trump categori pioneer roch lucenti well cheaper altern
compound bevacizumab eylea also seem easili absorb launch novarti
beovu show sign continu growth multipl indic remain posit
eylea expect continu grow excit aspect compani
next wave innov antibodi notabl dupix approv adult
atop dermat asthma nasal polypu view like receiv label expans
multipl allerg diseas indic expect dupix dupilumab gener revenu
peak signific upsid indic
longer term regeneron wholli own antibodi could contribut meaning
revenu earn growth period current compani invest
mode result earn cash flow convers revenu lag peer
industri anticip cash flow true earn improv period
profit antibodi collabor sanofi begin accumul
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani
price sale multipl larg cap high growth compani discount cash flow dcf
use averag larg cap larg molecul therapeut compani
rhhbi nv sni earn multipl ep appli
current ep estim give valu use slow
growth revenu multipl similar compani nv sni azn novo rhhbi
consensu sale appli revenu
estim give valu lastli dcf valuat given wacc
termin cash flow growth rate give present valu averag
three method current price target
risk view outlook valuat regeneron includ major chang
price reimburs coverag label competit posit eylea compani
main product today risk includ commerci develop disappoint
compani next partner program launch dupix kevzara well
continu weak demand price pressur compani cholesterol treatment praluent
lastli compani convert rel littl revenu cash flow today histori
return cash investor ultim may undermin valu stock
investor willing continu
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
sec gov compani websit present svbl analysi
follow safeti
bla file
us approv
potenti bla file
phase result
top-line pivot data
phase data
phase data
interim result
studi
phase data
phase data
phase data
phase data
phase data
phase data
data
phase data
phase data
phase data
brand
type event
event trial detail
date known
up/down
expect
fda decis pediatr ad patient
phase registr
us regulatori file
potenti bla file
updat phase data potenti
combo immunotherapi present
futur medic confer
interim analysi os expect
libtayo mono
manag report phase data futur
phase result follow safeti
svb leerink llc equiti research compani file
million
svb leerink llc partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target regeneron
method high growth larg cap biopharma ep multipl forma
ep rhhbi nv sni
svb leerink forma ep estim
impli price ep
equiti
number period
method larg cap biopharma forward multipl appli expect
revenu
larg cap high growth biopharma price/sal multipl
svb leerink revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
svb leerink llc research compani file factset
